CTU: A Phase 1, Open-label Dose Escalation and Dose-Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3L-001 Monotherapy in Subjects with HER2-Positive Advanced Solid Tumors.

  • Park, John (Primary Chief Investigator)
  • Chester, Catherine (Clinical Trial Unit Staff)
  • Chapman, Nicola (Clinical Trial Unit Staff)
  • TAIDI, Gina (Clinical Trial Unit Staff)
  • Martin, Lewis (Clinical Trial Unit Staff)

Project: Research

Project Details

Short titleD3L-001-100
AcronymD3L-001-100
StatusActive
Effective start/end date4/04/2419/03/29